IMCR Projected Dividend Yield

ADS/Immunocore Holdings PLC ( NASDAQ : IMCR )

Immunocore Holdings is a late-stage biotechnology company focusing on the development of a class of T cell receptors, or TCR, bispecific immunotherapies called ImmTAX, Immune mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, infectious and autoimmune. Co.'s platforms include: ImmTAC, which focuses on the treatment of solid tumors; ImmTAV, which includes IMC-I109V, its ImmTAV molecule targeting a conserved hepatitis B virus envelope antigen; and ImmTAAI, which utilizes its ImmTAX platform to generate product candidates designed to provide targeted immunosuppression for the treatment of autoimmune diseases.

20 YEAR PERFORMANCE RESULTS